Target intelligence / Profile preview

O-sialoglycoprotein endopeptidase (OSGE)

Target
OSGE
Molecular classification
Enzyme, Metalloprotease (specifically a neutral metalloprotease), Hydrolase (Enzyme Commission: EC 3.4.24.57)
01

Overview

O-sialoglycoprotein endopeptidase is a bacterial neutral metalloprotease, originally isolated from Pasteurella (Mannheimia) haemolytica, that specifically hydrolyzes O-sialoglycoproteins—proteins carrying clusters of negatively charged O-linked sialic acid residues. Its most characterized activity is the selective cleavage of the peptide bond between Arg^31 and Asp in human erythrocyte glycophorin A, but it also acts on other sialylated surface glycoproteins such as CD34, CD43, CD44, CD45, IL-7 receptor, selectin receptors, and certain tumor antigens. The enzyme does not cleave non-O-glycosylated proteins or those with only N-linked sugars, and its activity is inhibited by EDTA and certain sialate analogues, reflecting its metal ion (Zn^2+ dependent, though not directly activated) requirement. The enzyme is a valuable tool in glycobiology for removing or mapping O-sialoglycan-containing domains and for selective immunomagnetic separation of stem and immune cell populations[1][3][7][10].

Other names
glycoproteaseglycophorin A proteinaseglycoproteinasesialoglycoproteasesialoglycoproteinasePasteurella haemolytica glycoprotease
02

Mechanism of action

Cleaves peptide bonds specifically in O-sialoglycoproteins, most notably at the Arg^31-Asp bond in glycophorin A and other glycoproteins with O-linked sialic acids. Does not cleave non-O-glycosylated or N-linked glycoproteins

03

Biological functions

Cleavage of O-sialoglycoproteins (proteins with O-linked sialoglycans)Modification of cell surface glycoproteinsUseful in epitope mapping and cell separation studies
04

Disease associations

Other (not a direct disease target but a tool enzyme; produced by bacteria involved in animal infections, e.g., Mannheimia haemolytica in bovine pneumonia)Infection (relevant in the context of bacterial pathogenesis; no established direct therapeutic disease role)
05

Safety considerations

Primarily laboratory/research use; not employed in therapyAs a bacterial enzyme, potential biohazard if not handled according to lab safety protocolsIf used therapeutically (not standard), could disrupt cell surface glycoproteins leading to loss of key cellular interactions

Beyond the preview

Go deeper on O-sialoglycoprotein endopeptidase (OSGE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on O-sialoglycoprotein endopeptidase (OSGE).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call